26/03/2021 |
Itolizumab Safety and Efficacy Study in Covid 19 |
CIM |
Registered |
08/04/2021 |
VSSP in renal cell carcinoma |
CIM |
Registered |
18/06/2021 |
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM) |
CIM |
Registered outdated |
21/05/2021 |
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX |
CIM |
Registered outdated |
22/05/2021 |
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
CIM |
Registered outdated |
12/05/2021 |
CIMAvax-EGF in different maintenance schemes |
CIM |
Registered outdated |
18/06/2021 |
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
CIM |
Registered outdated |
30/06/2021 |
Itolizumab-Plasmapheresis in patients with COVID-19 |
CIM |
Registered |
21/06/2023 |
VSSPs in renal carcinoma. |
CIM |
Registered |
21/05/2021 |
Nimotuzumab in COVID-19 |
CIM |
Registered |
20/10/2021 |
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT |
CIM |
Registered |
21/03/2022 |
Post EUA study of Itolizumab in COVID-19 |
CIM |
Registered outdated |
20/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease |
CIM |
Registered |
22/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
CIM |
Registered |
16/08/2023 |
Her1 vaccine in metastatic colon and prostate cancer |
CIM |
Registered |
2012-09-17 |
iorEPOCIM-Stroke-Phase I |
CIMAB |
Registered outdated |
2013-02-01 |
Nimotuzumab in tumors of head and neck .Phase IV |
CIMAB |
Registered |
2013-02-01 |
Nimotuzumab for the treatment of high grade of malignancy tumors |
CIMAB |
Registered |
2013-02-26 |
ior EPOCIM ® in the management of anemia of the preterm infant.Phase IV. |
CIMAB |
Registered |
2011-11-11 |
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis. |
CIMAB |
Registered |